There were changes at the top and the bottom of last year’s top 20 pharma rankings by revenue. And, in between, Novo Nordisk made a significant leap, jumping five spots propelled by skyrocketing sales of its diabetes and obesity treatments Ozempic and Wegovy. Accounting for the changes at the high and low ends of the rankings were plummeting sales of COVID-19 products. | 2023 was all about diabetes and obesity drug sellers Novo Nordisk and Eli Lilly posting huge revenue gains as they were the only companies in the biopharma industry with double-digit gains. At the other end of the spectrum, sellers of COVID products saw dramatic decreases in revenue as Pfizer, the top revenue drugmaker in 2022, had a 41% decrease, while Moderna and BioNTech tumbled out of the top 20.
Source: Top 20 pharma companies by 2023 revenue | Fierce Pharma
